Cargando…
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials
BACKGROUND AND AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. Here, we evaluate the efficacy and safety of tofacitinib re-treatment following treatment interruption in patients with ulcerative colitis. METHODS: Here, patients with clinica...
Autores principales: | Panés, Julian, Vermeire, Séverine, Dubinsky, Marla C, Loftus, Edward V, Lawendy, Nervin, Wang, Wenjin, Salese, Leonardo, Su, Chinyu, Modesto, Irene, Guo, Xiang, Colombel, Jean-Frederic |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575053/ https://www.ncbi.nlm.nih.gov/pubmed/33884415 http://dx.doi.org/10.1093/ecco-jcc/jjab065 |
Ejemplares similares
-
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
por: Sandborn, William J., et al.
Publicado: (2021) -
Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
por: Sandborn, William J., et al.
Publicado: (2022) -
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019) -
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
por: Vermeire, Séverine, et al.
Publicado: (2020) -
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
por: Biedermann, Luc, et al.
Publicado: (2022)